Furthermore, the occurrence of EMT in NSCLC was detrimental to the enrichment of immunocompetent cells and would increase the release of immunosuppressive cytokines, such as TGF‐β60 to develop resistance to erlotinib target therapy through the TGFβ‐IL‐6 axis.61 The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.